Wall Street analyst estimates for ENDRA Life Sciences Inc. (NDRA): consensus price target, buy/hold/sell recommendations and forecasts for revenue, EPS and EBITDA for the upcoming fiscal years.
ENDRA Life Sciences Inc. specializes in advancing the capabilities of clinical diagnostic ultrasound. The company's primary development is thermo-acoustic enhanced ultrasound technology, which operates by emitting sound waves that echo off internal body components such as tissues, organs, and blood.
Analyst Consensus
| Strong Buy | 0 |
| Buy | 4 |
| Hold | 0 |
| Sell | 0 |
| Strong Sell | 0 |
| Total analysts | 4 |
| Avg rating (1-5) | 1.00 |
Valuation Ratios
| Price / Book | 1.11 |
| EV / EBITDA | -0.48 |
| Dividend Yield | 0.00% |
Income Statement (10y)
| Year | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $515582 | $351622 | $6174 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue | $235878 | $172782 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Gross Profit | $279704 | $178840 | $6174 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Research & Development | $495377 | $1.9M | $4.7M | $6.6M | $5.9M | $5.5M | $6.6M | $5.0M | $3.2M | $1.8M |
| Selling, General & Admin | $1.6M | $2.9M | $4.0M | $4.3M | $5.6M | $6.0M | $6.6M | $5.5M | $7.6M | $3.9M |
| Operating Expenses | $2.1M | $4.8M | $9.0M | $10.8M | $11.5M | $11.5M | $13.2M | $10.5M | $10.8M | $5.8M |
| Operating Income | -$1.8M | -$4.6M | -$9.0M | -$10.8M | -$11.5M | -$11.5M | -$13.2M | -$10.5M | -$10.8M | -$5.8M |
| EBITDA | -$1.7M | -$4.6M | -$9.0M | -$10.8M | -$11.3M | -$11.0M | -$12.9M | -$9.8M | -$11.3M | -$6.9M |
| Interest Expense | 0 | 0 | $729241 | $2.4M | $232426 | 0 | $21533 | 0 | 0 | 0 |
| Pre-tax Income | -$2.8M | -$5.4M | -$9.8M | -$13.3M | -$11.7M | -$11.2M | -$13.2M | -$10.1M | -$11.5M | -$7.0M |
| Income Tax | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Net Income | -$2.8M | -$5.4M | -$9.8M | -$13.3M | -$11.7M | -$11.2M | -$13.2M | -$10.1M | -$11.5M | -$7.0M |
| EPS | $-14.21 | $-27.47 | $-43.49 | $-41.48 | $-12.47 | $-5.47 | $-4.57 | $-5.89 | $-10.25 | $-8.93 |
| EPS (Diluted) | $-14.21 | $-27.47 | $-43.49 | $-41.48 | $-12.47 | $-5.47 | $-6.84 | $-5.89 | $-10.25 | $-8.93 |
| Shares Outstanding (Diluted) | $195351 | $195751 | $225243 | $374999 | $959611 | $2.0M | $1.9M | $1.7M | $1.1M | $787020 |
Price
| Price | $5.30 |
| Market Cap | $7M |
| Exchange | NASDAQ |
| Country | US |
Related companies: BBLG · BGMS · BNBX · DHAI · GCTK · HSCS · ISPC
Explore sector: Healthcare · Medical - Diagnostics & Research
More sections of NDRA: Overview · Financials · Valuation · Statistics · Technical · Ownership · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks